Difference between revisions of "Non-small cell lung cancer, BRAF-mutated"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "{| class="wikitable" style="width: 100%; text-align:center;" !Study !Evidence |-" to "{| class="wikitable" style="width: 100%; text-align:center;" !style="width: 50%"|Study !style="width: 50%"|Evidence |-")
m
Line 16: Line 16:
 
|}
 
|}
 
{{TOC limit|limit=3}}
 
{{TOC limit|limit=3}}
−
=Advanced or metastatic disease, BRAF inhibitor-naive=
+
=Advanced or metastatic disease, first-line=
  
 
==Dabrafenib & Trametinib {{#subobject:d08f40|Regimen=1}}==
 
==Dabrafenib & Trametinib {{#subobject:d08f40|Regimen=1}}==
Line 32: Line 32:
 
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
|-
 
|-
−
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993103/ Planchard et al. 2016 (BRF113928)]
+
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30679-4/fulltext Planchard et al. 2017 (BRF113928)]
 
|style="background-color:#91cf61"|Phase II
 
|style="background-color:#91cf61"|Phase II
 
|-
 
|-
−
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30679-4/fulltext Planchard et al. 2017]
+
|}
 +
====Chemotherapy====
 +
*[[Dabrafenib (Tafinlar)]] 150 mg PO BID
 +
*[[Trametinib (Mekinist)]] 2 mg PO once per day
 +
 
 +
'''Continued indefinitely'''
 +
 
 +
===References===
 +
# '''BRF113928:''' Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, Giannone V, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017 Oct;18(10):1307-1316. Epub 2017 Sep 11. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30679-4/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28919011 PubMed]
 +
 
 +
=Advanced or metastatic disease, previously treated, BRAF inhibitor-naive=
 +
 
 +
==Dabrafenib & Trametinib {{#subobject:05e601|Regimen=1}}==
 +
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#top|back to top]]
 +
|}
 +
===Regimen {{#subobject:c14c97|Variant=1}}===
 +
{| class="wikitable" style="color:white; background-color:#404040"
 +
|<small>'''FDA-recommended dose'''</small>
 +
|-
 +
|}
 +
{| class="wikitable" style="width: 100%; text-align:center;"
 +
!style="width: 50%"|Study
 +
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
 +
|-
 +
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993103/ Planchard et al. 2016 (BRF113928)]
 
|style="background-color:#91cf61"|Phase II
 
|style="background-color:#91cf61"|Phase II
 
|-
 
|-
Line 44: Line 70:
 
*[[Trametinib (Mekinist)]] 2 mg PO once per day
 
*[[Trametinib (Mekinist)]] 2 mg PO once per day
  
−
'''Continued until progression'''
+
'''Continued indefinitely'''
  
 
===References===
 
===References===
−
# Planchard D, Besse B, Groen HJ, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016 Jul;17(7):984-93. Epub 2016 Jun 6. '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993103/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27283860 PubMed]
+
# '''BRF113928:''' Planchard D, Besse B, Groen HJ, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016 Jul;17(7):984-93. Epub 2016 Jun 6. '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993103/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27283860 PubMed]
−
# Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, Giannone V, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017 Oct;18(10):1307-1316. Epub 2017 Sep 11. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30679-4/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28919011 PubMed]
 
  
 
[[Category:Non-small cell lung cancer regimens]]
 
[[Category:Non-small cell lung cancer regimens]]
 
[[Category:Biomarker-specific pages]]
 
[[Category:Biomarker-specific pages]]
 
[[Category:Thoracic cancers]]
 
[[Category:Thoracic cancers]]

Revision as of 17:17, 20 October 2018


Section editor
TravisOsterman.jpg
 Travis Osterman, DO, MS
Nashville, TN
Twitter: TravisOsterman
LinkedIn

Note: these are biomarker-specific regimens, please see the main NSCLC page for other regimens.

3 regimens on this page
3 variants on this page


Advanced or metastatic disease, first-line

Dabrafenib & Trametinib

back to top

Regimen

FDA-recommended dose
Study Evidence
Planchard et al. 2017 (BRF113928) Phase II

Chemotherapy

Continued indefinitely

References

  1. BRF113928: Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, Giannone V, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Dabrafenib plus trametinib in patients with previously untreated BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol. 2017 Oct;18(10):1307-1316. Epub 2017 Sep 11. link to original article PubMed

Advanced or metastatic disease, previously treated, BRAF inhibitor-naive

Dabrafenib & Trametinib

back to top

Regimen

FDA-recommended dose
Study Evidence
Planchard et al. 2016 (BRF113928) Phase II

All enrolled patients had BRAF p.V600E mutations and had progressed on 1 to 3 prior regimens.

Chemotherapy

Continued indefinitely

References

  1. BRF113928: Planchard D, Besse B, Groen HJ, Souquet PJ, Quoix E, Baik CS, Barlesi F, Kim TM, Mazieres J, Novello S, Rigas JR, Upalawanna A, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016 Jul;17(7):984-93. Epub 2016 Jun 6. contains verified protocol link to PMC article PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Non-small_cell_lung_cancer,_BRAF-mutated&oldid=32052"